| Title |
Tiotropium versus placebo for chronic obstructive pulmonary disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2014
|
| DOI | 10.1002/14651858.cd009285.pub3 |
| Pubmed ID | |
| Authors |
Charlotta Karner, Jimmy Chong, Phillippa Poole |
| Abstract |
Tiotropium is an anticholinergic agent which has gained widespread acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable chronic obstructive pulmonary disease (COPD). In the past few years there have been several systematic reviews of the efficacy of tiotropium, however, several new trials have compared tiotropium treatment with placebo, including those of a soft mist inhaler, making an update necessary. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 36% |
| United Kingdom | 2 | 18% |
| Unknown | 5 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 276 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| United States | 2 | <1% |
| Unknown | 272 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 42 | 15% |
| Student > Bachelor | 34 | 12% |
| Researcher | 33 | 12% |
| Student > Ph. D. Student | 29 | 11% |
| Other | 21 | 8% |
| Other | 49 | 18% |
| Unknown | 68 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 101 | 37% |
| Nursing and Health Professions | 24 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 6% |
| Psychology | 16 | 6% |
| Agricultural and Biological Sciences | 11 | 4% |
| Other | 30 | 11% |
| Unknown | 77 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2022.
All research outputs
#1,557,077
of 24,849,927 outputs
Outputs from Cochrane database of systematic reviews
#3,431
of 12,991 outputs
Outputs of similar age
#15,385
of 234,067 outputs
Outputs of similar age from Cochrane database of systematic reviews
#66
of 240 outputs
Altmetric has tracked 24,849,927 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,991 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.0. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,067 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 240 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.